{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T14:41:57Z","timestamp":1783521717217,"version":"3.55.0"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T00:00:00Z","timestamp":1671235200000},"content-version":"am","delay-in-days":350,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.ejca.2021.10.022","type":"journal-article","created":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T09:33:16Z","timestamp":1638437596000},"page":"235-242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Disease-specific outcomes after chimeric antigen receptor T-cell therapy"],"prefix":"10.1016","volume":"160","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5833-6728","authenticated-orcid":false,"given":"Jean","family":"Lemoine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Vic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1729-8213","authenticated-orcid":false,"given":"Roch","family":"Houot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2021.10.022_bib1","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.10.022_bib2","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.10.022_bib3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.10.022_bib4","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.7508","article-title":"Efficacy and safety of tisagenlecleucel (Tisa-cel) in adult patients (Pts) with relapsed\/refractory follicular lymphoma (r\/r FL): primary analysis of the phase 2 Elara trial","volume":"39","author":"Schuster","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.10.022_bib5","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.10.022_bib6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA- 1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.10.022_bib7","first-page":"40","article-title":"Primary analysis of Zuma-5: a phase 2 study of\u00a0axicabtagene ciloleucel (Axi-Cel) in patients with relapsed\/refractory (R\/R) indolent non-Hodgkin lymphoma (iNHL)","volume":"136","author":"Jacobson","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2021.10.022_bib8","series-title":"Definition of brexucabtagene autoleucel - NCI drug dictionary - national cancer Institute","year":"2011"},{"key":"10.1016\/j.ejca.2021.10.022_bib9","first-page":"1","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"6736","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2021.10.022_bib10","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.10.022_bib11","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2021.10.022_bib12","series-title":"Safety and preliminary efficacy in patients with relapsed\/refractory mantle cell lymphoma receiving lisocabtagene maraleucel in transcend NHL 001","author":"Palomba","year":"2020"},{"key":"10.1016\/j.ejca.2021.10.022_bib13","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-21-1559","article-title":"Overcoming intrinsic resistance of cancer cells to CAR T-cell killing","author":"Lemoine","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2021.10.022_bib14","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s13045-021-01209-9","article-title":"Born to survive: how cancer cells resist CAR T cell therapy","volume":"14","author":"Lemoine","year":"2021","journal-title":"J Hematol Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921011801?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921011801?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:33:36Z","timestamp":1760733216000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921011801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":14,"alternative-id":["S0959804921011801"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.10.022","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disease-specific outcomes after chimeric antigen receptor T-cell therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.10.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}